Proteomic profiling in schizophrenia: Enabling stratification for more effective treatment

Genome Medicine

Volumn 5, Issue 3, 2013, Pages

  Guest, Paul C ^a   Martins de Souza, Daniel ^b,c,d   Schwarz, Emanuel ^a   Rahmoune, Hassan ^a   Alsaif, Murtada ^a   Tomasik, Jakub ^a   Turck, Christoph W ^b   Bahn, Sabine ^a,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; ARGIPRESSIN; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CHROMOGRANIN A; GAMMA INTERFERON; GLUCOSE; GLUTATHIONE; GROWTH HORMONE; INSULIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METFORMIN; NEUROLEPTIC AGENT; PIOGLITAZONE; PLACEBO; PREALBUMIN; PROLACTIN; PROOPIOMELANOCORTIN; RALOXIFENE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; GLUCOSE TOLERANCE; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MASS SPECTROMETRY; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WEIGHT GAIN;

EID: 84875082538     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm429     Document Type: Review

References (95)

1. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158:518-526.
2. Wong EH, Yocca F, Smith MA, Lee CM. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int J Neuropsychopharmacol 2010, 13:1269-1284.
3. Lovatt A, Mason O, Brett C, Peters E. Psychotic-like experiences, appraisals, and trauma. J Nerv Ment Dis 2010, 198:813-819.
4. Izmailov R, Guest PC, Bahn S, Schwarz E. Algorithm development for diagnostic biomarker assays. Int Rev Neurobiol 2011, 101:279-298.
5. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006, 10:131-148.
6. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009, 259:151-163.
7. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 2010, 10:209-216.
8. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
9. Wu Z, Zhang XY, Wang H, Tang W, Xia Y, Zhang F, Liu J, Fu Y, Hu J, Chen Y, Liu L, Chen da C, Xiu MH, Kosten TR, He J. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36:34-38.
10. Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, Tongiorgi E, De Vanna M. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res 2011, 45:273-279.
11. English JA, Dicker P, Föcking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009, 9:3368-3382.
12. Föcking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry 2011, 68:477-488.
13. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, Wait R, Dunn MJ, Cotter DR. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008, 13:1102-1117.
14. Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry 2011, 16:1189-1202.
15. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 2011, 15:2067-2079.
16. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, Wayland MT, Umrania Y, Herberth M, Koethe D, van Beveren JM, Rothermundt M, McAllister G, Leweke FM, Steiner J, Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol Psychiatry 2010, 15:118-119.
17. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36:1092-1096.
18. Laughren TP. What's next after 50 years of psychiatric drug development: an FDA perspective. J Clin Psychiatry 2010, 71:1196-1204.
19. Ovens J. Funding for accelerating drug development initiative critical. Nat Rev Drug Discov 2006, 5:271.
20. Goodsaid F, Frueh FW. Implementing the U.S. FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen 2007, 48:354-358.
21. Goodsaid F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782.
22. Filiou MD, Martins-de-Souza D, Guest PC, Bahn S, Turck CW. To label or not to label: applications of quantitative proteomics in neuroscience research. Proteomics 2012, 12:736-747.
23. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2010, 15:1088-1100.
24. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, van Beveren NJ, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010, 5:39-47.
25. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012, 17:494-502.
26. Bendall SC, Simonds EF, Qiu P, Amir E-AD, Krutzik PO, Finck R. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696.
27. Wan C, Yang Y, Li H, La Y, Zhu H, Jiang L, Chen Y, Feng G, He L. Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res 2006, 5:3213-3216.
28. La YJ, Wan CL, Zhu H, Yang YF, Chen YS, Pan YX, Feng GY, He L. Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm 2007, 114:657-663.
29. Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
30. Zhang XY, Chen da C, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, Kosten TR. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr Res 2009, 113:151-157.
31. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One 2012, 7:e46368.
32. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H, Bahn S. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012, 2:e87.
33. Söderlund J, Schröder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009, 14:1069-1071.
34. Merrill JE. Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. Dev Neurosci 1992, 14:1-10.
35. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 2009, 35:959-972.
36. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007, 7:46.
37. Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R, Arzberger T, Kretzschmar H, Herrera-Marschitz M, Gruber O, Reynolds R, Falkai P, Gebicke-Haerter PJ. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 2011, 12:201-215.
38. Montejo AL. The need for routine physical health care in schizophrenia. Eur Psychiatry 2010, 25(Suppl 2):S3-5.
39. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, F Moreira JC, Teixeira AL, Lobato MI, Walz JC, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012, 46:819-824.
40. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
41. Fessel WJ, Solomon GF. Psychosis and systemic lupus erythematosus: a review of the literature and case reports. Calif Med 1960, 92:266-270.
42. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006, 163:521-528.
43. Jones AL, Mowry BJ, Pender MP, Greer JM. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol Cell Biol 2005, 83:9-17.
44. Sirota P, Firer MA, Schild K, Tanay A, Elizur A, Meytes D, Slor H. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 1993, 33:450-455.
45. Späth-Schwalbe E, Born J, Schrezenmeier H, Bornstein SR, Stromeyer P, Drechsler S, Fehm HL, Porzsolt F. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994, 79:1212-1214.
46. Straub RH, Buttgereit F, Cutolo M. Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation. Clin Exp Rheumatol 2011, 29:S23-31.
47. Bremner JD. Traumatic stress: effects on the brain. Dialogues Clin Neurosci 2006, 8:445-461.
48. Spijker AT, van Rossum EF. Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 2012, 95:179-186.
49. Müller N, Riedel M, Schwarz MJ. Psychotropic effects of COX-2 inhibitors - a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004, 37:266-269.
50. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007, 90:179-185.
51. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010, 121:118-124.
52. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010, 71:520-527.
53. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007, 24:481-485.
54. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, Navarro MA, San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004, 65:1335-1342.
55. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry 2006, 51:382-386.
56. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008, 93:572-577.
57. Herberth M, Koethe D, Cheng TM, Krzyszton ND, Schoeffmann S, Guest PC, Rahmoune H, Harris LW, Kranaster L, Leweke FM, Bahn S. Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol Psychiatry 2011, 16:848-859.
58. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007, 317:369-372.
59. Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 2005, 26(Suppl 1):31-35.
60. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 2007, 4:147-152.
61. Bello NT, Hajnal A. Alterations in blood glucose levels under hyperinsulinemia affect accumbens dopamine. Physiol Behav 2006, 88:138-145.
62. O'Malley D, Shanley LJ, Harvey J. Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology 2003, 44:855-863.
63. Hirvonen J, Virtanen KA, Nummenmaa L, Hannukainen JC, Honka M-J, Bucci M, Nesterov SV, Parkkola R, Rinne J, Iozzo P, Nuutila P. Effects of insulin on brain glucose metabolism in impaired glucose tolerance. Diabetes 2011, 60:443-447.
64. Hutton JC. Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases. Diabetologia 1994, 37(Suppl 2):S48-56.
65. Corcoran CM, Smith C, McLaughlin D, Auther A, Malaspina D, Cornblatt B. HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia. Schizophr Res 2012, 135:170-174.
66. Gorobets LN, Matrosova MI. Specialties of prolactin secretion and peripheral reproductive sex hormones in patients with of first episode of schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 2010, 110:17-22.
67. Goldman MB. The mechanism of life-threatening water imbalance in schizophrenia and its relationship to the underlying psychiatric illness. Brain Res Rev 2009, 61:210-220.
68. Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009, 30:548-557.
69. Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29:1065-1070.
70. Akiibinu MO, Ogundahunsi OA, Ogunyemi EO. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 2012, 5:169.
71. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006, 17:110-116.
72. Tannenbaum GS, Martin JB, Colle E. Ultradian growth hormone rhythm in the rat: effects of feeding, hyperglycemia, and insulin-induced hypoglycemia. Endocrinology 1976, 99:720-727.
73. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 2001, 24:278-290.
74. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.
75. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007, 64:2863-2886.
76. Nilsson BM, Hultman CM, Wiesel FA. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot Essent Fatty Acids 2006, 74:339-346.
77. Garcia GE, Gabbai FB, O'Connor DT, Dinh TQ, Kennedy B, Ziegler MG, Takiyyuddin MA. Does chromostatin influence catecholamine release or blood pressure in vivo?. Peptides 1994, 15:195-197.
78. Tatemoto K, Efendić S, Mutt V, Makk G, Feistner GJ, Barchas JD. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 1986, 324:476-478.
79. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976, 2:19-76.
80. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003, 59:19-27.
81. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 2005, 80:55-59.
82. Bahtiyar G, Weiss K, Sacerdote AS. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. Endocr Pract 2007, 13:601-608.
83. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011, 32:1626-1633.
84. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
85. Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr Res 2005, 79:251-256.
86. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000, 85:4650-4656.
87. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2011, 72:1552-1557.
88. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
89. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011, 7:9-37.
90. Jin H, Meyer J, Mudaliar S, Henry R, Khandrika S, Glorioso DK, Kraemer H, Jeste D. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry 2010, 71:1273-1278.
91. Shrivastava A, Johnston M, Bureau Y, Shah N. Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: is it a predictive factor?. Innov Clin Neurosci 2012, 9:17-21.
92. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2012, 2:e82.
93. Raposo NR, Ferreira AS, Gattaz WF. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry 2011, 44:169-172.
94. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 2012, 27:69-75.
95. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007, 43:497-509.